Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Journal of Gastrointestinal Cancer
Erschienen in:

22.07.2017 | Review Article

Is That Possible to Stop or Cease the NASH to Turn into HCC?

verfasst von: Ahmet Uygun

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Excerpt

We do not exactly know this because the etiopathogenesis of non-alcoholic steatohepatitis (NASH) is not completely known. But this progression can slow down by taking certain measures. …
Literatur
1.
Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implication. Gastroenterology. 2012;142:711–25.CrossRef
2.
Mc Cullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006;40:17–29.
3.
Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma (HCC) in non alcoholic fatty liver disease. A multicenter prospective study. Hepatology 2015; 24; 28363.
4.
Pisto P, Santaniemi M, Bloigu R, et al. Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study. BMJ Open. 2014;20:4967–73.
5.
Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patient with hepatocellular carcinoma in the U.S. Hepatology. 2014;59:2188–95.CrossRef
6.
White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342–59.CrossRef
7.
Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014;60:110–7.CrossRef
8.
Sorrentino P, D’Angelo S, Ferbo U, Micheli P, et al. Liver iron excess in patients with HCC developed on NASH. J Hepatol. 2009;50:351–7.CrossRef
9.
Duan XF, Tang P, Li Q, Yu ZT. Obesity, adipokines and hepatocellular carcinoma. Int J Cancer. 2013;13:1776–83.CrossRef
10.
Zambo V, Simon-Szabo L, Szelenyi P, Kereszturi et al. Lipotoxicity in the liver. World J. Hepatol 2013; 5: 550–557.CrossRef
11.
Henao-Mejia J, Elinav E, Jin C, Hao L, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482:179–85.CrossRef
12.
Oliveira CP, Stefano JT. Genetic polymorphisms and oxidative stress in NASH: a mini review. Clin res Hepatol Gastroenterol. 2015;39:35–40.CrossRef
13.
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J med. 2003;348:1625–38.CrossRef
14.
Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol. 2005;23:4742–54.CrossRef
15.
Karagozian R, Derdak Z, Baffy G. Obesity–associated mechanisms of hepatocarcinogenesis. Metabolism. 2014;63:607–17.CrossRef
16.
Schlesinger S, Aleksandrova K, Pischon T, et al. Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort. Int J Cancer. 2013;132:645–57.CrossRef
17.
Yasui K, Hashimoto E, Komorizono Y, et al. Characteristics of patients with NASH who develop HCC. Clin Gastroenterol Hepatol. 2011;9:428–33.CrossRef
18.
Adami HO, Chow WO, Nyren O, et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst. 1996;88:1472–7.CrossRef
19.
Nelson JE, Wilson L, Brunt EM, et al. Relationship between the pattern of hepatic iron deposition and histological severity in NAFLD. Hepatology. 2011;53:448–57.CrossRef
20.
Hsiao PJ, Kuo KK, Shin SJ, Yang YH, et al. Significant correlations between severe fatty liver and risk factors for metabolic syndrome. J Gastroenterol Hepatol. 2007;22:2118–23.CrossRef
21.
Mc Glynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011;15:223–43.CrossRef
22.
Scalera A, Tarantino G. Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? World J Gastroenterol. 2014;20:9217–28.PubMedPubMedCentral
23.
Speliotes EK, Yerges-Armstrong LM, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011;7:1324–38.CrossRef
24.
Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to NAFLD. Nat Genet. 2008;40:1461–5.CrossRef
25.
Singal AG, Manjunath H, Yopp AC, et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol. 2014;109:325–34.CrossRef
26.
Shen JH, Li YL, Li D, et al. The rs738409 (IL48M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis. J Lipid res. 2014:487–95.
27.
Zhu L, Baker SS, Gill C, et al. Characterization of the gut microbiome in NASH patients: a connection between endogenonus aicohol and NASH. Hepatology. 2013;57:601–9.CrossRef
28.
Ren Z, Xu S, Jiang J, Zheng S. A novel diagnosis for early HCC based on intestinal microbiome. 21st Annual Meeting of the İnternational Liver Transplant Society, Chicago, 2015.
29.
Dapito DH, Mencin A, Gwak GY, et al. Promotion of HCC by the intestinal microbiota and TLR4. Cancer Cell. 2012;21:504–16.CrossRef
30.
Yatsuji S, Hashimoto E, Tobari M, et al. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol. 2009;24:248–54.CrossRef
31.
Singh S, Singh PP, Singh AG, et al. Anti-diabetic medications and the risk of HCC: a systematic review and meta-analysis. Am J Gastroenterol. 2013;108:881–91.CrossRef
32.
Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of HCC in NAFLD: a multicenter prospective study. Hepatology. 2015;47:36–9.
33.
Reddy SK, Steel JL, Chen HW, et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology. 2012;55:1809–19.CrossRef
34.
Leung C, Yeoh SW, Patrick D, et al. Characteristics of HCC in cirrhotic and non-cirrhotic NAFLD. World J Gastroenterol. 2015;21:1189–96.CrossRef
35.
Torres DM, Harrison SA. NASH and non-cirrhotic HCC: fertile soil. Semin Liver dis. 2012;32:30–8.CrossRef
36.
Schutte K, Schulz C, Poranzke J, et al. Characterization and prognosis of patients with HCC in the non-cirrhotic liver. BMC Gastroenterol. 2014;14:117–25.CrossRef
37.
Chang CY, Hernandez-Prera JC, Roayaie S, Schwartz M, Thung SN. Changing epidemiology of hepatocellular adenoma in the United States: review of the literature. Int J Hepatol. 2013;604860
38.
Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of NASH: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134–40.CrossRef
39.
Marrero JA, Fontana RJ, Su GL, et al. NAFLD may be a common underlying liver disease in patients with HCC in the United States. Hepatology. 2002;3:1349–54.CrossRef
40.
Bertot LC, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 2016;17:774–88.CrossRef
41.
Chettouh H, Lequoy M, Fartoux L, et al. Hyperinsulinemia and insulin signalling in the pathogenesis and the clinical course of HCC. Liver Int. 2015;35:2203–17.CrossRef
42.
Zhao L. The gut microbiota and obesity: from correlation to causality. Nat rev Microbiol. 2013;11:639–47.CrossRef
43.
Dongiovanni P, Romeo S, Valenti L. HCC in NAFL: role of environmental and genetic factors. World J Gastroenterol. 2014;20:12945–55.CrossRef
44.
Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51:1820–32.CrossRef
45.
Yun YH, Lim MK, Won YJ, et al. Dietary preference, physical activity and cancer risk in men: national health insurance corporation study. BMC Cancer. 2008;8:366.CrossRef
46.
47.
Fedirko V, Duarte-Salles T, Bamia C, et al. Prediagnostic circulating vitamin D levels and risk of HCC in European populations: a nested case-control study. Hepatology. 2014;60:1222–30.CrossRef
48.
Turati F, Trichopoulos D, Polesel J, et al. Mediterranean diet and hepatocellular carcinoma. J Hepatol. 2014;60:606–11.CrossRef
49.
Dongiovanni P, Petta S, Mannisto V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015;63:705–12.CrossRef
50.
Zhang H, Gao C, Fang L, Zhao HC, Yao SK. Metformin and reduced risk of HCC in diabetic patients: a meta-analysis. Scand J Gastroenterol. 2013;48:78–87.CrossRef
51.
Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.CrossRef
52.
Pei Y, Zhang T, Renault V, Zhang X. An overview of HCC study by omics-based methods. Acta Biochim Biophys sin. 2009;41:1–15.CrossRef
53.
Takaki Y, Saito Y, Takasugi A, et al. Silencing of microRNA-122 is an early event during hepatocarcinogenesis from NASH. Cancer Sci. 2014;105:1254–60.CrossRef
54.
Liu YL, Patman GL, Leathart JB, et al. Carriage of the PNPLA3 rs738409 C > G polymorphism confers an increased risk of NAFLD associted HCC. J Hepatol. 2014;61:75–81.CrossRef
Metadaten
Titel
Is That Possible to Stop or Cease the NASH to Turn into HCC?
verfasst von
Ahmet Uygun
Publikationsdatum
22.07.2017
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 3/2017
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-017-9961-6

Weitere Artikel der Ausgabe 3/2017

Molecular Pathogenesis of Liver Cancer

  • Review Article

Cancer Stem Cells in Hepatocellular Carcinoma

  • Review Article

Radiological Response to the Locoregional Treatment in Hepatocellular Carcinoma: RECIST, mRECIST, and Others

  • Review Article

Enlighting the Shadow for Advanced Hepatocellular Carcinoma: Immunotherapy with Immune Checkpoint Inhibitors

  • Review Article

Validation of a Liver Index and Its Significance for HCC Aggressiveness

  • Original Research

Hepatocellular Cancer: Is Recurrence Inevitable?

  • Review Article

Neu im Fachgebiet Onkologie

CDK4/6-Inhibitoren bei Brustkrebs in die Zweitlinie aufschieben?

Ergebnisse einer Phase-III-Studie sprechen dafür, dass die Behandlung mit CDK4/6-Inhibitoren bei fortgeschrittenem HR-positivem, HER2-negativem Brustkrebs auch auf die Zweitlinie verschoben werden könnte, ohne die onkologischen Ergebnisse zu kompromittieren.

Cannabisextrakt verbessert Antiemese bei Chemotherapie

Sprechen Krebskranke auf die übliche Antiemese während einer Chemotherapie nicht ausreichend an, lohnt sich möglicherweise eine Behandlung mit Cannabisextrakt. In einer Phase-2/3-Studie ließ sich die antiemetische Response mit einem solchen Extrakt erheblich verbessern.

Veränderung der Brustdichte beeinflusst das Krebsrisiko

Die radiologische Dichte des Mammagewebes ist mit dem Risiko assoziiert, an Brustkrebs zu erkranken. Dabei wirken sich laut Ergebnissen einer Studie auch Dichteänderungen aus. Fünf Verlaufsmuster lassen sich dabei unterscheiden.

PMBCL mit CMR: Radiatio kann ohne Risiko weggelassen werden

Patienten mit primär mediastinalem B-Zell-Lymphom (PMBCL), die nach der Induktionstherapie eine komplette metabolische Remission (CMR) erreichen und keine konsolidierende Bestrahlung erhalten, müssen offenbar keine Überlebensnachteile fürchten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise